POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company
2 clinical trials · Sponsor
◉ Watch POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company
| Record | Firm | Date |
|---|---|---|
| FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER) (NCT05432193) | POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company | 2022-07-13 |
| Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment (NCT04647526) | POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company | 2021-02-25 |
Track POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company automatically
Every clearance here is in the API, with alerts when new ones post.